APO Research
Talk to an analyst

APO RESEARCH · REPORT

Quetiapine Fumarate Sustained Release Tablets

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Quetiapine Fumarate Sustained Release Tablets Market Analysis and Forecast 2026-2032

29 December 2025194 pages

Choose your research edition.

Industry ResearchQuetiapine Fumarate Sustained Release Tablets Industry Research Report 2026123 pages · $2,950 USDIndustry Growth & TrendsGlobal Quetiapine Fumarate Sustained Release Tablets Industry Growth and Trends Forecast to 2032104 pages · $3,450 USDMarket StructureGlobal Quetiapine Fumarate Sustained Release Tablets Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Quetiapine Fumarate Sustained Release Tablets Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Quetiapine Fumarate Sustained Release Tablets Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global Quetiapine Fumarate Sustained Release Tablets market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Quetiapine Fumarate Sustained Release Tablets is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Quetiapine Fumarate Sustained Release Tablets is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Quetiapine Fumarate Sustained Release Tablets is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Quetiapine Fumarate Sustained Release Tablets is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Quetiapine Fumarate Sustained Release Tablets include Dr. Reddy's Laboratories, Lupin Limited, Luye Pharma Limited, PHARMATHEN INVESTMENTS GROUP LIMITED, Seroquel, Torrent Pharmaceuticals, Mylan N.V., Sandoz and Sun Pharmaceutical Industries, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Quetiapine Fumarate Sustained Release Tablets, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Quetiapine Fumarate Sustained Release Tablets, also provides the revenue of main regions and countries. Of the upcoming market potential for Quetiapine Fumarate Sustained Release Tablets, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Quetiapine Fumarate Sustained Release Tablets revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Quetiapine Fumarate Sustained Release Tablets market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Quetiapine Fumarate Sustained Release Tablets revenue, projected growth trends, production technology, application and end-user industry.

Quetiapine Fumarate Sustained Release Tablets Segment by Company

Dr. Reddy's Laboratories

Lupin Limited

Luye Pharma Limited

PHARMATHEN INVESTMENTS GROUP LIMITED

Seroquel

Torrent Pharmaceuticals

Mylan N.V.

Sandoz

Sun Pharmaceutical Industries

Teva Pharmaceutical Industries

Quetiapine Fumarate Sustained Release Tablets Segment by Type

50mg

200mg

300mg

400mg

Quetiapine Fumarate Sustained Release Tablets Segment by Application

Hospital

Clinic

Others

Quetiapine Fumarate Sustained Release Tablets Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Quetiapine Fumarate Sustained Release Tablets market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Quetiapine Fumarate Sustained Release Tablets and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Quetiapine Fumarate Sustained Release Tablets.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Quetiapine Fumarate Sustained Release Tablets in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Quetiapine Fumarate Sustained Release Tablets company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Quetiapine Fumarate Sustained Release Tablets revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Quetiapine Fumarate Sustained Release Tablets Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. 50mg Major Player Table 3. 200mg Major Player Table 4. 300mg Major Player Table 5. 400mg Major Player Table 6. Global Quetiapine Fumarate Sustained Release Tablets Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 7. Hospital Major Player Table 8. Clinic Major Player Table 9. Others Major Player Table 10. Quetiapine Fumarate Sustained Release Tablets Industry Trends Table 11. Quetiapine Fumarate Sustained Release Tablets Industry Drivers Table 12. Quetiapine Fumarate Sustained Release Tablets Industry Opportunities and Challenges Table 13. Quetiapine Fumarate Sustained Release Tablets Industry Restraints Table 14. Global Quetiapine Fumarate Sustained Release Tablets Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 15. Global Quetiapine Fumarate Sustained Release Tablets Market Size by Region (2021-2026) & (US$ Million) Table 16. Global Quetiapine Fumarate Sustained Release Tablets Market Share by Region (2021-2026) Table 17. Global Quetiapine Fumarate Sustained Release Tablets Market Size by Region (2027-2032) & (US$ Million) Table 18. Global Quetiapine Fumarate Sustained Release Tablets Market Share by Region (2027-2032) Table 19. Global Quetiapine Fumarate Sustained Release Tablets Revenue by Players (US$ Million) & (2021-2026) Table 20. Global Quetiapine Fumarate Sustained Release Tablets Revenue Market Share by Players (2021-2026) Table 21. Global Quetiapine Fumarate Sustained Release Tablets Key Players Ranking, 2024 VS 2025 VS 2026 Table 22. Global Quetiapine Fumarate Sustained Release Tablets Key Players Headquarters & Area Served Table 23. Global Quetiapine Fumarate Sustained Release Tablets Players, Product Type & Application Table 24. Global Quetiapine Fumarate Sustained Release Tablets Players Establishment Date Table 25. Global Players Market Concentration Ratio (CR5 and HHI) Table 26. Global Quetiapine Fumarate Sustained Release Tablets by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 27. Global Quetiapine Fumarate Sustained Release Tablets Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Quetiapine Fumarate Sustained Release Tablets Revenue by Type (2021-2026) & (US$ Million) Table 29. Global Quetiapine Fumarate Sustained Release Tablets Revenue by Type (2027-2032) & (US$ Million) Table 30. Global Quetiapine Fumarate Sustained Release Tablets Revenue Market Share by Type (2021-2026) Table 31. Global Quetiapine Fumarate Sustained Release Tablets Revenue Market Share by Type (2027-2032) Table 32. Global Quetiapine Fumarate Sustained Release Tablets Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Quetiapine Fumarate Sustained Release Tablets Revenue by Application (2021-2026) & (US$ Million) Table 34. Global Quetiapine Fumarate Sustained Release Tablets Revenue by Application (2027-2032) & (US$ Million) Table 35. Global Quetiapine Fumarate Sustained Release Tablets Revenue Market Share by Application (2021-2026) Table 36. Global Quetiapine Fumarate Sustained Release Tablets Revenue Market Share by Application (2027-2032) Table 37. Dr. Reddy's Laboratories Company Information Table 38. Dr. Reddy's Laboratories Business Overview Table 39. Dr. Reddy's Laboratories Quetiapine Fumarate Sustained Release Tablets Revenue and Gross Margin (US$ Million) & (2021-2026) Table 40. Dr. Reddy's Laboratories Quetiapine Fumarate Sustained Release Tablets Product Portfolio Table 41. Dr. Reddy's Laboratories Recent Development Table 42. Lupin Limited Company Information Table 43. Lupin Limited Business Overview Table 44. Lupin Limited Quetiapine Fumarate Sustained Release Tablets Revenue and Gross Margin (US$ Million) & (2021-2026) Table 45. Lupin Limited Quetiapine Fumarate Sustained Release Tablets Product Portfolio Table 46. Lupin Limited Recent Development Table 47. Luye Pharma Limited Company Information Table 48. Luye Pharma Limited Business Overview Table 49. Luye Pharma Limited Quetiapine Fumarate Sustained Release Tablets Revenue and Gross Margin (US$ Million) & (2021-2026) Table 50. Luye Pharma Limited Quetiapine Fumarate Sustained Release Tablets Product Portfolio Table 51. Luye Pharma Limited Recent Development Table 52. PHARMATHEN INVESTMENTS GROUP LIMITED Company Information Table 53. PHARMATHEN INVESTMENTS GROUP LIMITED Business Overview Table 54. PHARMATHEN INVESTMENTS GROUP LIMITED Quetiapine Fumarate Sustained Release Tablets Revenue and Gross Margin (US$ Million) & (2021-2026) Table 55. PHARMATHEN INVESTMENTS GROUP LIMITED Quetiapine Fumarate Sustained Release Tablets Product Portfolio Table 56. PHARMATHEN INVESTMENTS GROUP LIMITED Recent Development Table 57. Seroquel Company Information Table 58. Seroquel Business Overview Table 59. Seroquel Quetiapine Fumarate Sustained Release Tablets Revenue and Gross Margin (US$ Million) & (2021-2026) Table 60. Seroquel Quetiapine Fumarate Sustained Release Tablets Product Portfolio Table 61. Seroquel Recent Development Table 62. Torrent Pharmaceuticals Company Information Table 63. Torrent Pharmaceuticals Business Overview Table 64. Torrent Pharmaceuticals Quetiapine Fumarate Sustained Release Tablets Revenue and Gross Margin (US$ Million) & (2021-2026) Table 65. Torrent Pharmaceuticals Quetiapine Fumarate Sustained Release Tablets Product Portfolio Table 66. Torrent Pharmaceuticals Recent Development Table 67. Mylan N.V. Company Information Table 68. Mylan N.V. Business Overview Table 69. Mylan N.V. Quetiapine Fumarate Sustained Release Tablets Revenue and Gross Margin (US$ Million) & (2021-2026) Table 70. Mylan N.V. Quetiapine Fumarate Sustained Release Tablets Product Portfolio Table 71. Mylan N.V. Recent Development Table 72. Sandoz Company Information Table 73. Sandoz Business Overview Table 74. Sandoz Quetiapine Fumarate Sustained Release Tablets Revenue and Gross Margin (US$ Million) & (2021-2026) Table 75. Sandoz Quetiapine Fumarate Sustained Release Tablets Product Portfolio Table 76. Sandoz Recent Development Table 77. Sun Pharmaceutical Industries Company Information Table 78. Sun Pharmaceutical Industries Business Overview Table 79. Sun Pharmaceutical Industries Quetiapine Fumarate Sustained Release Tablets Revenue and Gross Margin (US$ Million) & (2021-2026) Table 80. Sun Pharmaceutical Industries Quetiapine Fumarate Sustained Release Tablets Product Portfolio Table 81. Sun Pharmaceutical Industries Recent Development Table 82. Teva Pharmaceutical Industries Company Information Table 83. Teva Pharmaceutical Industries Business Overview Table 84. Teva Pharmaceutical Industries Quetiapine Fumarate Sustained Release Tablets Revenue and Gross Margin (US$ Million) & (2021-2026) Table 85. Teva Pharmaceutical Industries Quetiapine Fumarate Sustained Release Tablets Product Portfolio Table 86. Teva Pharmaceutical Industries Recent Development Table 87. North America Quetiapine Fumarate Sustained Release Tablets Revenue by Type (2021-2026) & (US$ Million) Table 88. North America Quetiapine Fumarate Sustained Release Tablets Revenue by Type (2027-2032) & (US$ Million) Table 89. North America Quetiapine Fumarate Sustained Release Tablets Revenue by Application (2021-2026) & (US$ Million) Table 90. North America Quetiapine Fumarate Sustained Release Tablets Revenue by Application (2027-2032) & (US$ Million) Table 91. North America Quetiapine Fumarate Sustained Release Tablets Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 92. North America Quetiapine Fumarate Sustained Release Tablets Revenue by Country (2021-2026) & (US$ Million) Table 93. North America Quetiapine Fumarate Sustained Release Tablets Revenue by Country (US$ Million) & (2027-2032) Table 94. Europe Quetiapine Fumarate Sustained Release Tablets Revenue by Type (2021-2026) & (US$ Million) Table 95. Europe Quetiapine Fumarate Sustained Release Tablets Revenue by Type (2027-2032) & (US$ Million) Table 96. Europe Quetiapine Fumarate Sustained Release Tablets Revenue by Application (2021-2026) & (US$ Million) Table 97. Europe Quetiapine Fumarate Sustained Release Tablets Revenue by Application (2027-2032) & (US$ Million) Table 98. Europe Quetiapine Fumarate Sustained Release Tablets Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 99. Europe Quetiapine Fumarate Sustained Release Tablets Revenue by Country (2021-2026) & (US$ Million) Table 100. Europe Quetiapine Fumarate Sustained Release Tablets Revenue by Country (US$ Million) & (2027-2032) Table 101. China Quetiapine Fumarate Sustained Release Tablets Revenue by Type (2021-2026) & (US$ Million) Table 102. China Quetiapine Fumarate Sustained Release Tablets Revenue by Type (2027-2032) & (US$ Million) Table 103. China Quetiapine Fumarate Sustained Release Tablets Revenue by Application (2021-2026) & (US$ Million) Table 104. China Quetiapine Fumarate Sustained Release Tablets Revenue by Application (2027-2032) & (US$ Million) Table 105. Asia Quetiapine Fumarate Sustained Release Tablets Revenue by Type (2021-2026) & (US$ Million) Table 106. Asia Quetiapine Fumarate Sustained Release Tablets Revenue by Type (2027-2032) & (US$ Million) Table 107. Asia Quetiapine Fumarate Sustained Release Tablets Revenue by Application (2021-2026) & (US$ Million) Table 108. Asia Quetiapine Fumarate Sustained Release Tablets Revenue by Application (2027-2032) & (US$ Million) Table 109. Asia Quetiapine Fumarate Sustained Release Tablets Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 110. Asia Quetiapine Fumarate Sustained Release Tablets Revenue by Region (US$ Million) & (2021-2026) Table 111. Asia Quetiapine Fumarate Sustained Release Tablets Revenue by Region (US$ Million) & (2027-2032) Table 112. SAMEA Quetiapine Fumarate Sustained Release Tablets Revenue by Type (2021-2026) & (US$ Million) Table 113. SAMEA Quetiapine Fumarate Sustained Release Tablets Revenue by Type (2027-2032) & (US$ Million) Table 114. SAMEA Quetiapine Fumarate Sustained Release Tablets Revenue by Application (2021-2026) & (US$ Million) Table 115. SAMEA Quetiapine Fumarate Sustained Release Tablets Revenue by Application (2027-2032) & (US$ Million) Table 116. SAMEA Quetiapine Fumarate Sustained Release Tablets Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 117. SAMEA Quetiapine Fumarate Sustained Release Tablets Revenue by Country (2021-2026) & (US$ Million) Table 118. SAMEA Quetiapine Fumarate Sustained Release Tablets Revenue by Country (US$ Million) & (2027-2032) Table 119. Research Programs/Design for This Report Table 120. Authors List of This Report Table 121. Secondary Sources Table 122. Primary Sources List of Figures Figure 1. Quetiapine Fumarate Sustained Release Tablets Image Figure 2. Global Quetiapine Fumarate Sustained Release Tablets Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Quetiapine Fumarate Sustained Release Tablets Market Size Share 2021 VS 2025 VS 2032 Figure 4. 50mg Image Figure 5. 200mg Image Figure 6. 300mg Image Figure 7. 400mg Image Figure 8. Global Quetiapine Fumarate Sustained Release Tablets Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 9. Global Quetiapine Fumarate Sustained Release Tablets Market Size Share 2021 VS 2025 VS 2032 Figure 10. Hospital Image Figure 11. Clinic Image Figure 12. Others Image Figure 13. Global Quetiapine Fumarate Sustained Release Tablets Market Size (US$ Million) & (2021-2032) Figure 14. Global Quetiapine Fumarate Sustained Release Tablets Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 15. Global Quetiapine Fumarate Sustained Release Tablets Market Share by Region: 2021 VS 2025 VS 2032 Figure 16. Global Quetiapine Fumarate Sustained Release Tablets Players Revenue Share Top 10 and Top 5 in 2025 Figure 17. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 18. Global Quetiapine Fumarate Sustained Release Tablets Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Quetiapine Fumarate Sustained Release Tablets Revenue Market Share 2021 VS 2025 VS 2032 Figure 20. Global Quetiapine Fumarate Sustained Release Tablets Revenue Market Share by Type (2021-2032) Figure 21. Global Quetiapine Fumarate Sustained Release Tablets Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 22. Global Quetiapine Fumarate Sustained Release Tablets Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 23. Global Quetiapine Fumarate Sustained Release Tablets Revenue Market Share by Application (2021-2032) Figure 24. North America Quetiapine Fumarate Sustained Release Tablets Revenue YoY Growth (2021-2032) & (US$ Million) Figure 25. North America Quetiapine Fumarate Sustained Release Tablets Revenue Share by Type (2021-2032) Figure 26. North America Quetiapine Fumarate Sustained Release Tablets Revenue Share by Application (2021-2032) Figure 27. North America Quetiapine Fumarate Sustained Release Tablets Revenue Share by Country (2021-2032) Figure 28. United States Quetiapine Fumarate Sustained Release Tablets Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Canada Quetiapine Fumarate Sustained Release Tablets Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Mexico Quetiapine Fumarate Sustained Release Tablets Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Europe Quetiapine Fumarate Sustained Release Tablets Revenue YoY Growth (2021-2032) & (US$ Million) Figure 32. Europe Quetiapine Fumarate Sustained Release Tablets Revenue Share by Type (2021-2032) Figure 33. Europe Quetiapine Fumarate Sustained Release Tablets Revenue Share by Application (2021-2032) Figure 34. Europe Quetiapine Fumarate Sustained Release Tablets Revenue Share by Country (2021-2032) Figure 35. Germany Quetiapine Fumarate Sustained Release Tablets Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. France Quetiapine Fumarate Sustained Release Tablets Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. U.K. Quetiapine Fumarate Sustained Release Tablets Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Italy Quetiapine Fumarate Sustained Release Tablets Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Spain Quetiapine Fumarate Sustained Release Tablets Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Russia Quetiapine Fumarate Sustained Release Tablets Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Netherlands Quetiapine Fumarate Sustained Release Tablets Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Nordic Countries Quetiapine Fumarate Sustained Release Tablets Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. China Quetiapine Fumarate Sustained Release Tablets Revenue YoY Growth (2021-2032) & (US$ Million) Figure 44. China Quetiapine Fumarate Sustained Release Tablets Revenue Share by Type (2021-2032) Figure 45. China Quetiapine Fumarate Sustained Release Tablets Revenue Share by Application (2021-2032) Figure 46. Asia Quetiapine Fumarate Sustained Release Tablets Revenue YoY Growth (2021-2032) & (US$ Million) Figure 47. Asia Quetiapine Fumarate Sustained Release Tablets Revenue Share by Type (2021-2032) Figure 48. Asia Quetiapine Fumarate Sustained Release Tablets Revenue Share by Application (2021-2032) Figure 49. Asia Quetiapine Fumarate Sustained Release Tablets Revenue Share by Region (2021-2032) Figure 50. Japan Quetiapine Fumarate Sustained Release Tablets Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. South Korea Quetiapine Fumarate Sustained Release Tablets Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. India Quetiapine Fumarate Sustained Release Tablets Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Australia Quetiapine Fumarate Sustained Release Tablets Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Taiwan Quetiapine Fumarate Sustained Release Tablets Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Southeast Asia Quetiapine Fumarate Sustained Release Tablets Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. SAMEA Quetiapine Fumarate Sustained Release Tablets Revenue YoY Growth (2021-2032) & (US$ Million) Figure 57. SAMEA Quetiapine Fumarate Sustained Release Tablets Revenue Share by Type (2021-2032) Figure 58. SAMEA Quetiapine Fumarate Sustained Release Tablets Revenue Share by Application (2021-2032) Figure 59. SAMEA Quetiapine Fumarate Sustained Release Tablets Revenue Share by Country (2021-2032) Figure 60. Brazil Quetiapine Fumarate Sustained Release Tablets Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Argentina Quetiapine Fumarate Sustained Release Tablets Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Chile Quetiapine Fumarate Sustained Release Tablets Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Colombia Quetiapine Fumarate Sustained Release Tablets Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Peru Quetiapine Fumarate Sustained Release Tablets Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Saudi Arabia Quetiapine Fumarate Sustained Release Tablets Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Israel Quetiapine Fumarate Sustained Release Tablets Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. UAE Quetiapine Fumarate Sustained Release Tablets Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Turkey Quetiapine Fumarate Sustained Release Tablets Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Iran Quetiapine Fumarate Sustained Release Tablets Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Egypt Quetiapine Fumarate Sustained Release Tablets Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • 50mg
  • 200mg
  • 300mg
  • 400mg
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • Dr. Reddy's Laboratories
  • Lupin Limited
  • Luye Pharma Limited
  • PHARMATHEN INVESTMENTS GROUP LIMITED
  • Seroquel
  • Torrent Pharmaceuticals
  • Mylan N.V.
  • Sandoz
  • Sun Pharmaceutical Industries
  • Teva Pharmaceutical Industries

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Quetiapine Fumarate Sustained Release Tablets Market by Type
  3. 1.2.1 Global Quetiapine Fumarate Sustained Release Tablets Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 50mg
  5. 1.2.3 200mg
  6. 1.2.4 300mg
  7. 1.2.5 400mg
  8. 1.3 Quetiapine Fumarate Sustained Release Tablets Market by Application
  9. 1.3.1 Global Quetiapine Fumarate Sustained Release Tablets Market Size by Application, 2021 VS 2025 VS 2032
  10. 1.3.2 Hospital
  11. 1.3.3 Clinic
  12. 1.3.4 Others
  13. 1.4 Assumptions and Limitations
  14. 1.5 Study Goals and Objectives
2 Quetiapine Fumarate Sustained Release Tablets Market Dynamics
  1. 2.1 Quetiapine Fumarate Sustained Release Tablets Industry Trends
  2. 2.2 Quetiapine Fumarate Sustained Release Tablets Industry Drivers
  3. 2.3 Quetiapine Fumarate Sustained Release Tablets Industry Opportunities and Challenges
  4. 2.4 Quetiapine Fumarate Sustained Release Tablets Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Quetiapine Fumarate Sustained Release Tablets Market Perspective (2021-2032)
  2. 3.2 Global Quetiapine Fumarate Sustained Release Tablets Growth Trends by Region
  3. 3.2.1 Global Quetiapine Fumarate Sustained Release Tablets Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Quetiapine Fumarate Sustained Release Tablets Market Size by Region (2021-2026)
  5. 3.2.3 Global Quetiapine Fumarate Sustained Release Tablets Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Quetiapine Fumarate Sustained Release Tablets Revenue by Players
  2. 4.1.1 Global Quetiapine Fumarate Sustained Release Tablets Revenue by Players (2021-2026)
  3. 4.1.2 Global Quetiapine Fumarate Sustained Release Tablets Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Quetiapine Fumarate Sustained Release Tablets Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Quetiapine Fumarate Sustained Release Tablets Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Quetiapine Fumarate Sustained Release Tablets Key Players Headquarters & Area Served
  7. 4.4 Global Quetiapine Fumarate Sustained Release Tablets Players, Product Type & Application
  8. 4.5 Global Quetiapine Fumarate Sustained Release Tablets Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Quetiapine Fumarate Sustained Release Tablets Market CR5 and HHI
  11. 4.6.3 2025 Quetiapine Fumarate Sustained Release Tablets Tier 1, Tier 2, and Tier 3
5 Quetiapine Fumarate Sustained Release Tablets Market Size by Type
  1. 5.1 Global Quetiapine Fumarate Sustained Release Tablets Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Quetiapine Fumarate Sustained Release Tablets Revenue by Type (2021-2032)
  3. 5.3 Global Quetiapine Fumarate Sustained Release Tablets Revenue Market Share by Type (2021-2032)
6 Quetiapine Fumarate Sustained Release Tablets Market Size by Application
  1. 6.1 Global Quetiapine Fumarate Sustained Release Tablets Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Quetiapine Fumarate Sustained Release Tablets Revenue by Application (2021-2032)
  3. 6.3 Global Quetiapine Fumarate Sustained Release Tablets Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Dr. Reddy's Laboratories
  2. 7.1.1 Dr. Reddy's Laboratories Company Information
  3. 7.1.2 Dr. Reddy's Laboratories Business Overview
  4. 7.1.3 Dr. Reddy's Laboratories Quetiapine Fumarate Sustained Release Tablets Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Dr. Reddy's Laboratories Quetiapine Fumarate Sustained Release Tablets Product Portfolio
  6. 7.1.5 Dr. Reddy's Laboratories Recent Developments
  7. 7.2 Lupin Limited
  8. 7.2.1 Lupin Limited Company Information
  9. 7.2.2 Lupin Limited Business Overview
  10. 7.2.3 Lupin Limited Quetiapine Fumarate Sustained Release Tablets Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Lupin Limited Quetiapine Fumarate Sustained Release Tablets Product Portfolio
  12. 7.2.5 Lupin Limited Recent Developments
  13. 7.3 Luye Pharma Limited
  14. 7.3.1 Luye Pharma Limited Company Information
  15. 7.3.2 Luye Pharma Limited Business Overview
  16. 7.3.3 Luye Pharma Limited Quetiapine Fumarate Sustained Release Tablets Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Luye Pharma Limited Quetiapine Fumarate Sustained Release Tablets Product Portfolio
  18. 7.3.5 Luye Pharma Limited Recent Developments
  19. 7.4 PHARMATHEN INVESTMENTS GROUP LIMITED
  20. 7.4.1 PHARMATHEN INVESTMENTS GROUP LIMITED Company Information
  21. 7.4.2 PHARMATHEN INVESTMENTS GROUP LIMITED Business Overview
  22. 7.4.3 PHARMATHEN INVESTMENTS GROUP LIMITED Quetiapine Fumarate Sustained Release Tablets Revenue and Gross Margin (2021-2026)
  23. 7.4.4 PHARMATHEN INVESTMENTS GROUP LIMITED Quetiapine Fumarate Sustained Release Tablets Product Portfolio
  24. 7.4.5 PHARMATHEN INVESTMENTS GROUP LIMITED Recent Developments
  25. 7.5 Seroquel
  26. 7.5.1 Seroquel Company Information
  27. 7.5.2 Seroquel Business Overview
  28. 7.5.3 Seroquel Quetiapine Fumarate Sustained Release Tablets Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Seroquel Quetiapine Fumarate Sustained Release Tablets Product Portfolio
  30. 7.5.5 Seroquel Recent Developments
  31. 7.6 Torrent Pharmaceuticals
  32. 7.6.1 Torrent Pharmaceuticals Company Information
  33. 7.6.2 Torrent Pharmaceuticals Business Overview
  34. 7.6.3 Torrent Pharmaceuticals Quetiapine Fumarate Sustained Release Tablets Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Torrent Pharmaceuticals Quetiapine Fumarate Sustained Release Tablets Product Portfolio
  36. 7.6.5 Torrent Pharmaceuticals Recent Developments
  37. 7.7 Mylan N.V.
  38. 7.7.1 Mylan N.V. Company Information
  39. 7.7.2 Mylan N.V. Business Overview
  40. 7.7.3 Mylan N.V. Quetiapine Fumarate Sustained Release Tablets Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Mylan N.V. Quetiapine Fumarate Sustained Release Tablets Product Portfolio
  42. 7.7.5 Mylan N.V. Recent Developments
  43. 7.8 Sandoz
  44. 7.8.1 Sandoz Company Information
  45. 7.8.2 Sandoz Business Overview
  46. 7.8.3 Sandoz Quetiapine Fumarate Sustained Release Tablets Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Sandoz Quetiapine Fumarate Sustained Release Tablets Product Portfolio
  48. 7.8.5 Sandoz Recent Developments
  49. 7.9 Sun Pharmaceutical Industries
  50. 7.9.1 Sun Pharmaceutical Industries Company Information
  51. 7.9.2 Sun Pharmaceutical Industries Business Overview
  52. 7.9.3 Sun Pharmaceutical Industries Quetiapine Fumarate Sustained Release Tablets Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Sun Pharmaceutical Industries Quetiapine Fumarate Sustained Release Tablets Product Portfolio
  54. 7.9.5 Sun Pharmaceutical Industries Recent Developments
  55. 7.10 Teva Pharmaceutical Industries
  56. 7.10.1 Teva Pharmaceutical Industries Company Information
  57. 7.10.2 Teva Pharmaceutical Industries Business Overview
  58. 7.10.3 Teva Pharmaceutical Industries Quetiapine Fumarate Sustained Release Tablets Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Teva Pharmaceutical Industries Quetiapine Fumarate Sustained Release Tablets Product Portfolio
  60. 7.10.5 Teva Pharmaceutical Industries Recent Developments
8 North America
  1. 8.1 North America Quetiapine Fumarate Sustained Release Tablets Revenue (2021-2032)
  2. 8.2 North America Quetiapine Fumarate Sustained Release Tablets Revenue by Type (2021-2032)
  3. 8.2.1 North America Quetiapine Fumarate Sustained Release Tablets Revenue by Type (2021-2026)
  4. 8.2.2 North America Quetiapine Fumarate Sustained Release Tablets Revenue by Type (2027-2032)
  5. 8.3 North America Quetiapine Fumarate Sustained Release Tablets Revenue Share by Type (2021-2032)
  6. 8.4 North America Quetiapine Fumarate Sustained Release Tablets Revenue by Application (2021-2032)
  7. 8.4.1 North America Quetiapine Fumarate Sustained Release Tablets Revenue by Application (2021-2026)
  8. 8.4.2 North America Quetiapine Fumarate Sustained Release Tablets Revenue by Application (2027-2032)
  9. 8.5 North America Quetiapine Fumarate Sustained Release Tablets Revenue Share by Application (2021-2032)
  10. 8.6 North America Quetiapine Fumarate Sustained Release Tablets Revenue by Country
  11. 8.6.1 North America Quetiapine Fumarate Sustained Release Tablets Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Quetiapine Fumarate Sustained Release Tablets Revenue by Country (2021-2026)
  13. 8.6.3 North America Quetiapine Fumarate Sustained Release Tablets Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Quetiapine Fumarate Sustained Release Tablets Revenue (2021-2032)
  2. 9.2 Europe Quetiapine Fumarate Sustained Release Tablets Revenue by Type (2021-2032)
  3. 9.2.1 Europe Quetiapine Fumarate Sustained Release Tablets Revenue by Type (2021-2026)
  4. 9.2.2 Europe Quetiapine Fumarate Sustained Release Tablets Revenue by Type (2027-2032)
  5. 9.3 Europe Quetiapine Fumarate Sustained Release Tablets Revenue Share by Type (2021-2032)
  6. 9.4 Europe Quetiapine Fumarate Sustained Release Tablets Revenue by Application (2021-2032)
  7. 9.4.1 Europe Quetiapine Fumarate Sustained Release Tablets Revenue by Application (2021-2026)
  8. 9.4.2 Europe Quetiapine Fumarate Sustained Release Tablets Revenue by Application (2027-2032)
  9. 9.5 Europe Quetiapine Fumarate Sustained Release Tablets Revenue Share by Application (2021-2032)
  10. 9.6 Europe Quetiapine Fumarate Sustained Release Tablets Revenue by Country
  11. 9.6.1 Europe Quetiapine Fumarate Sustained Release Tablets Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Quetiapine Fumarate Sustained Release Tablets Revenue by Country (2021-2026)
  13. 9.6.3 Europe Quetiapine Fumarate Sustained Release Tablets Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Quetiapine Fumarate Sustained Release Tablets Revenue (2021-2032)
  2. 10.2 China Quetiapine Fumarate Sustained Release Tablets Revenue by Type (2021-2032)
  3. 10.2.1 China Quetiapine Fumarate Sustained Release Tablets Revenue by Type (2021-2026)
  4. 10.2.2 China Quetiapine Fumarate Sustained Release Tablets Revenue by Type (2027-2032)
  5. 10.3 China Quetiapine Fumarate Sustained Release Tablets Revenue Share by Type (2021-2032)
  6. 10.4 China Quetiapine Fumarate Sustained Release Tablets Revenue by Application (2021-2032)
  7. 10.4.1 China Quetiapine Fumarate Sustained Release Tablets Revenue by Application (2021-2026)
  8. 10.4.2 China Quetiapine Fumarate Sustained Release Tablets Revenue by Application (2027-2032)
  9. 10.5 China Quetiapine Fumarate Sustained Release Tablets Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Quetiapine Fumarate Sustained Release Tablets Revenue (2021-2032)
  2. 11.2 Asia Quetiapine Fumarate Sustained Release Tablets Revenue by Type (2021-2032)
  3. 11.2.1 Asia Quetiapine Fumarate Sustained Release Tablets Revenue by Type (2021-2026)
  4. 11.2.2 Asia Quetiapine Fumarate Sustained Release Tablets Revenue by Type (2027-2032)
  5. 11.3 Asia Quetiapine Fumarate Sustained Release Tablets Revenue Share by Type (2021-2032)
  6. 11.4 Asia Quetiapine Fumarate Sustained Release Tablets Revenue by Application (2021-2032)
  7. 11.4.1 Asia Quetiapine Fumarate Sustained Release Tablets Revenue by Application (2021-2026)
  8. 11.4.2 Asia Quetiapine Fumarate Sustained Release Tablets Revenue by Application (2027-2032)
  9. 11.5 Asia Quetiapine Fumarate Sustained Release Tablets Revenue Share by Application (2021-2032)
  10. 11.6 Asia Quetiapine Fumarate Sustained Release Tablets Revenue by Country
  11. 11.6.1 Asia Quetiapine Fumarate Sustained Release Tablets Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Quetiapine Fumarate Sustained Release Tablets Revenue by Country (2021-2026)
  13. 11.6.3 Asia Quetiapine Fumarate Sustained Release Tablets Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Quetiapine Fumarate Sustained Release Tablets Revenue (2021-2032)
  2. 12.2 SAMEA Quetiapine Fumarate Sustained Release Tablets Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Quetiapine Fumarate Sustained Release Tablets Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Quetiapine Fumarate Sustained Release Tablets Revenue by Type (2027-2032)
  5. 12.3 SAMEA Quetiapine Fumarate Sustained Release Tablets Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Quetiapine Fumarate Sustained Release Tablets Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Quetiapine Fumarate Sustained Release Tablets Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Quetiapine Fumarate Sustained Release Tablets Revenue by Application (2027-2032)
  9. 12.5 SAMEA Quetiapine Fumarate Sustained Release Tablets Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Quetiapine Fumarate Sustained Release Tablets Revenue by Country
  11. 12.6.1 SAMEA Quetiapine Fumarate Sustained Release Tablets Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Quetiapine Fumarate Sustained Release Tablets Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Quetiapine Fumarate Sustained Release Tablets Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst